Clinical Updates on Immune-directed Therapies in MS: Expert Insights & Real World Evidence

Released On
April, 2020

Expires On
April, 2021

Media Type

Completion Time
60 minutes


Multiple Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Letters & Sciences and Postgraduate Institute for Medicine.

Supported by an independent educational grant from EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Neurologists and MS nurse specialists, as well as other clinicians treating and managing patients with MS.

Program Overview

Recent advances in the field of immunology and the increasing recognition of inflammatory pathways are re-shaping the conceptualization of multiple sclerosis (MS), with potential implications of new agents within the current landscape of treatment options. This CME/CNE activity features clinicians and researchers who will provide expert insights and updated evidence for immune-directed strategies in MS. Their presentations will describe the rationale for immune system reset along with supporting clinical evidence, and identify risks and benefits of current and emerging DMTs, including understanding of complications (i.e., infections, malignancy potential), as well as strategies for optimizing sequencing of therapies in individualized MS patient care.

Learning Objectives

After participating in this accredited satellite symposium, the learner should be able to:

  • Describe critical advances and emerging immune-directed therapies that will change the therapeutic approach to MS.
  • Review the immunologic rationale, safety, and clinical efficacy of supporting an immune system reset.
  • Identify clinical considerations when evaluating risks and benefits in deciding on DMT therapy.
  • Summarize the concept of immunosenescence and the importance of vigilance in monitoring the risk of infections especially in older MS patients.
  • Using real-world patient case challenges, discuss strategies to therapeutic optimization and patient selection, as well as ongoing safety monitoring and AE management of patients with RMS.


Mark Freedman, MSc, MD, FANA, FAAN, FRCPC, Co-Chair

Senior Scientist, Neuroscience Program
Ottawa Hospital Research Institute
Professor of Medicine, Neurology
University of Ottawa
Director, MS Research Unit, Neurology
Ottawa Hospital-General Campus
Ottawa, Canada

Patricia K. Coyle, MD, FAAN, FANA, Co-Chair

Professor and Interim Chair, Dept. of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York

Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Letters & Sciences. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To receive acknowledgement for participating in this activity, learners must complete the posttest and evaluation form.

Continuing Nursing Education

Letters & Sciences is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission (ANCC) on Accreditation.

This activity is designated for 1.0 contact hours.

To obtain the full number of CNE contact hour(s), the learner must participate in the entire activity and complete the posttest and evaluation form.

Financial Disclosures

It is the policy of Letters & Sciences and the Postgraduate Institute of Medicine to ensure balance, independence, and scientific rigor in all educational activities/programs. Those who may have the opportunity to influence content of this CME/CNE program (e.g. planners, faculty, authors, reviewers, and others) must disclose all relevant, significant financial relationships with commercial entities so that the providers may identify and resolve any conflicts of interest prior to the program.

Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of product(s), device(s) or clinical strategies to the participants at the time of the presentations. The faculty has disclosed the following:

Patricia K. Coyle, MD, FAAN, FANA

  • Has served as a consultant for: Accordant, Alexion, Bayer, Biogen Idec, EMD Serono, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, and TG Therapeutics.
  • Has received research support from: Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis, and PCORI.

Mark S. Freedman, MSc, MD, FANA, FAAN, FRCPC

  • Has received research or educational grants from: Genzyme
  • Has received honoraria or consultation fee from: Actelion (J&J), Alexion, Atara Biotherapeutics, Adamas, Biogen Idec, Celgene (BMS), EMD Serono, Hoffman La-Roche, Novartis, Sanofi-Genzyme.
  • Has served as member of a company advisory board, board of directors or other similar group: Actelion (J&J), Alexion, Atara Biotherapeutics, Bayer Healthcare, Biogen Idec, Celgene (BMS), Genzyme, Novartis, Sanofi-Aventis.
  • Has participated in a company sponsored speaker’s bureau for :EMD Serono, Genzyme

Letters & Sciences and Postgraduate Institute for Medicine

  • As content managers/members of the curriculum committee, report no relationships with commercial interests.

In accordance with the ACCME and ANCC standards to identify and resolve any potential conflicts of interest, to assure fair balance, independence and objectivity, and to instill scientific rigor in all activities/programs, all presentations, with any potential for conflict of interest, have been reviewed by two external reviewers. These external reviewers, who have no potential conflicts of interest, have determined that no bias exists in these presentations. These external reviewers are:

Shannon L. DeVita, MSN, RN, CNL, DNP

Nurse Practitioner
San Diego, California

Michele Nichols, PharmD

Pharmacy Consultant
Private Practice
Raritan, New Jersey

Disclosure of Unlabeled Use

The audience is advised that one or more sections in this continuing education activity may contain references to devices and/or protocols or clinical strategies that are unlabeled, investigational, or unapproved by the FDA. Healthcare professionals should note that the use of information presented that is outside of current approved labeling is considered experimental and are advised to consult current prescribing information. The faculty is required to disclose any unlabeled, investigational, and/or unapproved uses or therapies that are discussed.

Patricia K. Coyle, MD, FAAN, FANA

Has agreed to disclose any unlabeled/unapproved uses of drugs or products in her presentation.

Mark S. Freedman, MSc, MD, FANA, FAAN, FRCPC

Has agreed to disclose any unlabeled/unapproved uses of drugs or products in his presentation.

Instructions for Participation and Credit

Generic instructions are part of the site, but you may wish to include specific instructions such as the following. Participation in this activity is free. Understand the material, pass the intra-activity questions and complete an evaluation to receive credit. Passing grade is 80% and you are limited to 5 attempts. There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form. Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Further, participants are advised that the educational content contained herein was developed by and reflects the opinions of the presenters and faculty, and does not necessarily reflect the opinions or recommendations of the providers, the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), or the grantor. Accredited status does not imply endorsement of any commercial products, agents, and/or therapeutic strategies discussed in conjunction with the educational activity.